ZENFlex-Registry to Evaluate the Outcome of Bare Metal Stent-assisted Angioplasty

Atherosclerosis of Femoral Artery Clinical Trial

Official title:

ZENFlex-Registry to Evaluate the Outcome of Bare Metal Stent-assisted Angioplasty in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03751527
• Other study ID #: 201805
• Status: Recruiting
• Phase: N/A
• Start date: December 31, 2018
• Est. completion date: December 2023

Study information

• Verified date: August 2021
• Source: Zhejiang Zylox Medical Device Co., Ltd.
• Contact: Summer Zheng, Bachelor
• Phone: +8613601399119
• Email: summer.zheng[@]zyloxmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, multi-center, single-arm registry to evaluate the safety and efficacy of bare metal stent-assisted percutaneous transluminal angioplasty (PTA) in the treatment of superficial femoral and/or proximal popliteal artery (P1) lesions in patients with symptomatic peripheral artery disease

Description:

The purpose of this registry is to collect acute and follow-up (up to 12 months) safety and efficacy data on the ZENFlex™ Peripheral Stent System in the stent-assisted angioplasty treatment of patients with de novo or restenotic lesion(s) of the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA, P1 segment) when used according to IFU. Up to 100 subjects will be enrolled in this study at up to 5 sites in Germany.

This study is a prospective, single-arm observational registry and does not include an active control arm. Therefore, no formal sample size calculation has been performed. All subjects will be evaluated at pre-discharge and during clinical follow-up visits 6 (182 ± 30 days) and 12 (365 ± 30 days) months post-procedure.

Primary endpoints are patency rate after one year and composite of freedom from device and procedure-related death through 12 months post procedure as well as freedom from both target limb major amputation and clinically-driven target lesion revascularization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2023
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Patient is = 18 years old at the time of consent. 2. Subject has provided written informed consent prior to participation in the study, understands the purpose of this study and agrees to comply with all protocol-specified examinations and follow-up appointments.

3. Rutherford Classification Category 2-4. Subjects with Rutherford Class 2 have gone through a conservative therapy without success. 4. De novo stenotic, restenotic or occlusive lesion(s) located in the superficial femoral artery and/or proximal popliteal artery (P1 segment) suitable for stenting after PTA.

5. Lesion location starts distal to CFA bifurcation (below origin of deep femoral artery) and should not extend beyond the P1 segment of the popliteal artery.

6. Lesion(s) is/are located at least 2 cm from any stent if target limb was already previously stented.

7. >70 % diameter stenosis or occlusion by visual angiographic estimate. 8. Patent inflow (treatment of inflow is allowed before treatment of the target lesion if successful).

9. Patent ipsilateral popliteal artery (P2 and P3 segments) and at least 1 patent infrapopliteal artery in continuity to ankle. 10. Target reference vessel diameter = 4

• = 7.0 mm.

Exclusion Criteria:

• Patients will be excluded from the registry if any of the following criteria is met:

1. Target Lesion previously tested with a stent or surgery.

2. Rutherford Classification Category 0, 1, 5 or 6.

3. Inability to tolerate antithrombotic or antiplatelet therapies.

4. Known allergy or contraindication to contrast medium that, in the opinion of the investigator, can't be adequately pre-medicated.

5. Non-dilatable severely calcified lesion.

6. Known hypersensitivity to nitinol and/or its components (e.g. nickel, titanium).

7. Acute or subacute thrombus in the target lesion.

8. Documented life expectancy < 13 months

9. Pregnancy or female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding.

10. Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up.

11. Myocardial infarction or stroke within 90 days prior to index procedure.

12. Hypercoagulable state.

13. Patient is currently enrolled in any other clinical investigational trial(s).

14. Use of alternative therapy in target lesion during index procedure, e.g. atherectomy, lysis therapy, laser therapy, DES, re-entry-devices, cutting / scoring balloon

Related Conditions & MeSH terms

• Atherosclerosis
• Atherosclerosis of Femoral Artery

Intervention

Device:
• ZENFLEX peripheral stent system
The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.

Locations

Country	Name	City	State
Germany	Popescu Diakoniekrankenhaus Halle gGmbH Klinik für Innere Medizin	Halle

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Zylox Medical Device Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patency rate	patency rate after one year defined as absence of clinically driven TLR (due to symptoms and drop of ABI of = 20% or > 0.15 when compared to post-procedure baseline) or restenosis with PVR > 2.4 evaluated by Duplex Ultrasound	12 (365 ± 30 days) months
Primary	Procedure-related death	Composite of freedom from device and procedure-related death through 12 months post procedure as well as freedom from both target limb major amputation and clinically-driven target lesion revascularization?	12 (365 ± 30 days) months
Secondary	TLR rate at 6 and 12months	The ratio of either repeat percutaneous or surgical revascularization for target lesions	6 (182 ± 30 days) and 12 (365 ± 30 days) months
Secondary	Sustained clinical improvement	an improvement shift in the Rutherford classification of one class in amputation and TVR free surviving patients at 12 months.	12 (365 ± 30 days) months
Secondary	WIQ at 6 and 12 months	Walking capacity assessment by Walking Impairment Questionnaire (WIQ) at 6 and 12 months vs. baseline	6 (182 ± 30 days) and 12 (365 ± 30 days) months
Secondary	Duplex-defined binary restenosis (PSVR >2.4) at 6 and 12 months or at any time of re-intervention	Duplex-defined binary restenosis (PSVR >2.4) of the target lesion post-procedure and at 6 and 12 months or at any time of re-intervention	6 (182 ± 30 days) and 12 (365 ± 30 days) months